Translational Psychiatry
October 6, 2026
Nadia S. Hejazi, Mina Kheirkhah, Robin Chholak et al.
Insomnia and anxiety frequently co-occur with treatment-resistant depression (TRD). This study examined short-term changes in depression, anxiety, and insomnia symptoms post-ketamine in TRD and their inter-relationships. Seventy-one patients with TRD were assessed at baseline and 24 h after intravenous ketamine (0.5 mg/kg). Depression, anxiety, and insomnia were measured using the...
Brain Research Bulletin
October 6, 2026
Ziyi Hua, Yongqiang Shu, Li Li et al.
INTRODUCTION: This study investigated changes in multiband amplitude of low-frequency fluctuations in patients with major depressive disorder following a 2-week combination treatment regimen of esketamine and sertraline, and examined the associations between ALFF changes and clinical symptom improvement. METHODS: Forty patients with major depressive disorder (MDD) received esketamine (0.25...
Pharmacopsychiatry
October 2, 2026
Masami Murao, Daiki Setoyama, Yasuyuki Matsumoto et al.
Abstract This study investigated the antisuicidal effects of repeated intravenous ketamine in patients with treatment-resistant depression and explored associations between suicidal ideation and temporal changes in selected plasma biomarkers to identify potential biomarkers. This secondary analysis of an open-label trial included outpatients with treatment-resistant depression who received four...
International Journal of Pharmaceutical and Clinical Research
October 1, 2026
H Gayathri, J Nivedhya, K Purushothama Reddy et al.
Aim: To assess the effectiveness of ketamine-based treatment for adults with treatment-resistant depression in terms of the persistence of antidepressant responses or remission after treatment discontinuation. Data Sources: PubMed/MEDLINE database search was performed to select randomized clinical trials that assessed the effect of ketamine interventions on TRD in adults. Study Selection: The...
Psychedelics
October 1, 2026
David S. Mathai, Brian Pilecki, Hadi Zaki et al.
In 2019, the U.S. Food and Drug Administration (FDA) approved a patented formulation and delivery method of esketamine, the S-enantiomer of ketamine, for patients with treatment-resistant depression (TRD). While ketamine-based treatments share similarities with serotonin 2 A receptor-mediated “classic psychedelics” like psilocybin regarding subjective drug effects and stimulation of...
The International Journal of Medical Science and Health Research
September 29, 2026
Arby Shafara Sekundaputra
Introduction: Treatment-resistant depression (TRD) affects approximately one-third of patients with major depressive disorder and accounts for disproportionate disability and mortality. Electroconvulsive therapy (ECT) has long been the definitive intervention, whereas subanaesthetic intravenous ketamine has emerged as a rapid-acting alternative. Direct head-to-head evidence has accumulated...
CNS Spectrums
September 28, 2026
Magda Malewska-Kasprzak, Filip Rybakowski, Monika Dmitrzak-Weglarz
Intravenous ketamine is a rapid-acting intervention for treatment-resistant depression (TRD) in adults with major depressive disorder and bipolar disorder (BD). While efficacy is established, a comprehensive integration of clinical, neurophysiological, biomarker, metabolic, and cognitive predictors remains lacking, limiting precision CNS-targeted therapy. To synthesize recent evidence on...
Progress in neuro-psychopharmacology & biological psychiatry
September 26, 2026
Kuan-I Liu, Wei-Chen Lin, Cheng-Ta Li et al.
We examined symptom-level treatment effects and exploratory symptom networks after ketamine in treatment-resistant depression. This post hoc analysis pooled 132 participants assigned to ketamine 0.5 mg/kg or protocol-specific control (66 each) from saline-controlled 2017 and midazolam-controlled 2023 trials. Baseline- and trial-adjusted models assessed Montgomery-Åsberg Depression Rating Scale...
Journal of Education, Health and Sport
September 24, 2026
Anna Kamosińska, Julia Pająk, Olga Sławatyniec et al.
Treatment-resistant depression (TRD) in adolescents remains a major clinical challenge because of the limited efficacy of conventional antidepressants and the high risk of suicidal behavior. Ketamine has emerged as a rapidly acting antidepressant with a unique glutamatergic mechanism, promoting neuroplasticity and reducing neuroinflammation. Clinical studies demonstrate significant symptom...
Journal of Affective Disorders
September 23, 2026
Erin Curran, Kristina T. Kumpf, Mina Ansari et al.
Ketamine/esketamine produce rapid antidepressant effects, with growing interest in how acute subjective experiences and the surrounding set and setting shape clinical outcomes. Little is known about how audiovisual adjustments during ketamine/esketamine treatment influence comfort, tolerability, or patient experience, despite their common use in clinical practice. Virtual reality (VR) is one...